TXP Research Group, Universidad Cardenal Herrera-CEU, CEU Universities, 12006 Castellón de la Plana, Spain.
Proyecto Amigó, 12006 Castelló de la Plana, Spain.
Int J Environ Res Public Health. 2022 May 30;19(11):6695. doi: 10.3390/ijerph19116695.
The objective of the study was to evaluate the efficacy of an animal-assisted-therapy (AAT) program in patients diagnosed with schizophrenia-spectrum disorders and substance-use disorders in residential treatment in order to intervene in the remission of negative and positive symptoms and improve quality of life and adherence to treatment, favouring the clinical stabilization of patients who participate in the AAT program, within the context of a mental-illness-treatment device. This was a quasi-experimental prospective study with intersubject and intrasubject factors. The sample comprised 36 patients (21 in the experimental group and 15 in the control group) who were evaluated at three time points (in the 3rd, 6th, and 10th sessions). The program lasted 3 months and consisted of 10 sessions that were implemented once a week, with a maximum participation of 10 patients per group. The participants were evaluated with the Positive and Negative Syndrome Scale (PANSS) for schizophrenia and the Life Skills Profile-20 (LSP-20) questionnaire. We observed a decrease in the positive symptoms of psychosis (F: 27.80, p = 0.001) and an improvement in functionality (F: 26.70, p < 0.001) as the sessions progressed. On the basis of these results, we concluded that AAT seems to be valid as a coadjuvant therapy as part of the rehabilitation processes of patients diagnosed with schizophrenia and addiction-spectrum disorders (dual diagnosis).
本研究旨在评估动物辅助疗法(AAT)方案在接受住院治疗的精神分裂症谱系障碍和物质使用障碍患者中的疗效,以便干预负面和正面症状的缓解,提高生活质量和治疗依从性,促进参与 AAT 方案的患者的临床稳定,该方案是一种精神疾病治疗装置。这是一项具有主体间和主体内因素的准实验前瞻性研究。样本包括 36 名患者(实验组 21 名,对照组 15 名),他们在三个时间点(第 3、6 和 10 次治疗)进行评估。该方案持续 3 个月,共 10 次,每周实施一次,每组最多有 10 名患者参加。参与者使用阳性和阴性症状量表(PANSS)评估精神分裂症和生活技能概况-20(LSP-20)问卷。我们观察到精神病阳性症状(F:27.80,p = 0.001)和功能改善(F:26.70,p < 0.001)随着治疗的进行而逐渐减少。基于这些结果,我们得出结论,AAT 似乎可以作为一种辅助治疗方法,作为精神分裂症和物质使用障碍(双重诊断)患者康复过程的一部分。